Tirzepatide, sold as the FDA-approved brand Zepbound™ for chronic weight management and as Mounjaro® for type 2 diabetes, is also available as a compounded medication through licensed U.S. pharmacies. Like other GLP-1 and GIP receptor medications, it comes with a well-documented side effect profile, most of it gastrointestinal, along with a smaller set of less common but more serious warnings. Knowing what is common, what is rare, and when a symptom is worth a call to your clinician can make starting or continuing treatment feel less uncertain.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation from a licensed clinician who knows your health history.
Why gastrointestinal effects are the most common
Tirzepatide activates both GLP-1 and GIP receptors, hormone pathways that slow digestion and reduce appetite. That same mechanism is a large part of why gastrointestinal symptoms show up so often: slower stomach emptying can translate into nausea, a feeling of fullness, or changes in bowel habits while the digestive system adjusts to the medication. This pattern is consistent across GLP-1-based treatments and is not unique to tirzepatide; our overview of side effects of GLP-1 medications covers the same underlying mechanism in more general terms.
Because the effect is tied to how the medication works, gastrointestinal symptoms are expected rather than automatically a sign that something has gone wrong, though that does not mean every symptom should be ignored. The sections below walk through what the label lists as common, what is considered less common or serious, and where the line sits for contacting a clinician.
Common side effects listed on the label
Gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation are among the most commonly reported side effects in the Zepbound™ and Mounjaro® prescribing information. Other commonly reported effects include abdominal pain, injection-site reactions, decreased appetite, and fatigue. Most people who notice these effects describe them as mild to moderate, though individual experience varies and some people notice very little at all.
The table below groups these effects by how often they tend to be reported and what is generally recommended if they occur. It is an educational overview, not a complete list of every labeled side effect, and it does not replace the full prescribing information or your clinician's guidance.
| Category | Examples | Typical timing | What to do |
|---|---|---|---|
| Most commonly reported | Nausea, diarrhea, vomiting, constipation, abdominal pain | Often most noticeable during dose increases | Mention to your clinician; often manageable without stopping treatment |
| Other common effects | Injection-site reactions, fatigue, decreased appetite | Can occur at any point in treatment | Report if persistent or bothersome |
| Serious warnings | Pancreatitis, gallbladder disease, dehydration with possible kidney injury, hypoglycemia with certain diabetes medicines | Can occur at any time | Contact your clinician promptly |
| Boxed warning | Thyroid C-cell tumors (seen in rodent studies) | Contraindication, not an acute symptom | Not recommended with personal or family history of MTC or MEN 2 |
If you are also deciding between the FDA-approved product and a compounded version, our comparison of compounded tirzepatide vs. Zepbound™ looks at how the two compare beyond side effects alone.
Want to know if tirzepatide could work for you?
Less common and serious warnings
Beyond the common gastrointestinal effects, the Zepbound™ and Mounjaro® labels carry a boxed warning, the FDA's strongest form of warning, about the risk of thyroid C-cell tumors that were seen in rodent studies. Because of this, tirzepatide is not recommended for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not known whether tirzepatide causes thyroid C-cell tumors in humans.
Other labeled warnings include pancreatitis (inflammation of the pancreas), gallbladder disease, dehydration with possible kidney injury related to gastrointestinal side effects, and hypoglycemia (low blood sugar) when tirzepatide is used together with certain diabetes medicines such as insulin or sulfonylureas. Serious hypersensitivity reactions have also been reported. These are far less common than the gastrointestinal effects described above, but they are the reason the label asks patients and clinicians to stay alert for specific warning signs rather than assuming every symptom will pass on its own.
How side effects relate to dose changes
Gastrointestinal effects are most often reported during dose escalation, the period when the dose is being raised in planned steps, and they tend to ease for many people as the body adjusts to each new level, though this varies from person to person. Our explainer on how tirzepatide dosing works walks through the labeled step-up schedule in detail.
Because of this pattern, a clinician may respond to bothersome side effects by slowing the pace of future dose increases, staying at a current dose longer than originally planned, or in some cases stepping back to a lower dose, rather than automatically stopping treatment. Side effects that appear right after an increase and then settle over the following days or weeks follow a fairly typical pattern; symptoms that are severe or are not improving are a different matter, covered in the final section below.
Compounded tirzepatide and side effect reporting
Not everyone taking tirzepatide is prescribed the FDA-approved Zepbound™ or Mounjaro® brand products. Tirzepatide is also available as a compounded medication, sometimes prescribed when a patient has a specific clinical need that the commercially available product does not meet. Compounded medications are not FDA-approved but may be prescribed by independent licensed physicians when clinically appropriate. Our guide to what is compounded tirzepatide explains what that distinction means in practice.
FDA-approved brand products, Wegovy®, Ozempic®, Mounjaro®, and Zepbound™, have each been evaluated by the FDA for safety, effectiveness, and quality, including the side-effect data summarized in this article. Compounded versions share the same active ingredient but have not gone through that same FDA evaluation, so if you are prescribed a compounded version, use the general side effect profile described here as a starting point for a conversation with your clinician, since your own experience may differ.
When to contact a clinician
Contact your clinician promptly if you develop severe or persistent abdominal pain, with or without vomiting, which can be a sign of pancreatitis; pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can point to a gallbladder problem; symptoms of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, or difficulty breathing; or signs of dehydration, such as dizziness or a significant reduction in urination, especially alongside ongoing vomiting or diarrhea.
Also reach out if nausea, vomiting, or diarrhea is severe, is not improving, or is affecting your ability to eat, drink, or take other medications as prescribed, and let your clinician know about any new or unusual symptom even if you are not sure it is related to treatment. Do not change your own dose, skip a scheduled check-in, or stop treatment abruptly without talking to your clinician first.
The bottom line
Most people who take tirzepatide, whether as the FDA-approved Zepbound™ or Mounjaro® or as a compounded version, experience gastrointestinal side effects such as nausea, diarrhea, or constipation, especially around dose increases, and these are generally the most common and most manageable effects on the label. Less common but more serious warnings, including a boxed warning about thyroid C-cell tumors seen in rodent studies, pancreatitis, gallbladder disease, and dehydration-related kidney injury, are far less frequent but are the reason to stay alert for specific warning signs. Severe or persistent symptoms are always worth a call to your clinician rather than waiting them out. You can find more articles like this one in our Weight Management section.
Important Safety Information
Indication. Zepbound™ (tirzepatide) is FDA-approved for chronic weight management in adults with obesity, or with overweight and at least one weight-related medical condition, used along with a reduced-calorie diet and increased physical activity. Tirzepatide is also FDA-approved as Mounjaro® for type 2 diabetes. Compounded tirzepatide is not FDA-approved.
Common side effects. The most commonly reported side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions, decreased appetite, and fatigue; these are often more noticeable in the days after a dose increase.
Warnings. Zepbound™ and Mounjaro® carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other warnings include the risk of pancreatitis, gallbladder problems, severe gastrointestinal disease, acute kidney injury related to dehydration from gastrointestinal side effects, hypoglycemia when used with insulin or sulfonylureas, and serious hypersensitivity reactions.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
What are the most common tirzepatide side effects?
Gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation are among the most commonly reported side effects in the Zepbound™ and Mounjaro® prescribing information. Abdominal pain, injection-site reactions, decreased appetite, and fatigue are also commonly reported.
How long do tirzepatide side effects last?
Gastrointestinal effects are most often reported during dose escalation and tend to ease for many people as the body adjusts to each new dose, though this varies from person to person. Symptoms that are severe or are not improving are a different matter and are worth a call to your clinician.
What is the boxed warning for tirzepatide?
The Zepbound™ and Mounjaro® labels carry a boxed warning about the risk of thyroid C-cell tumors seen in rodent studies. Tirzepatide is not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Can tirzepatide cause pancreatitis or gallbladder problems?
Yes, pancreatitis and gallbladder disease are both labeled warnings for tirzepatide. Contact your clinician promptly for severe or persistent abdominal pain, or for signs of a gallbladder problem such as pain in the upper right abdomen, fever, or yellowing of the skin or eyes.
Does compounded tirzepatide have the same side effects as Zepbound™ or Mounjaro®?
Compounded tirzepatide shares the same active ingredient, but compounded medications are not FDA-approved, while FDA-approved brand products are evaluated by the FDA for safety, effectiveness, and quality. Use the side effect profile described here as a starting point for a conversation with your clinician, since your own experience may differ.
When should I call my clinician about tirzepatide side effects?
Call promptly for severe or persistent abdominal pain, signs of a serious allergic reaction, signs of dehydration, or nausea, vomiting, or diarrhea that is severe or is affecting your ability to eat, drink, or take other medications as prescribed.
